{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:36:03Z","timestamp":1773693363912,"version":"3.50.1"},"reference-count":24,"publisher":"Tohoku University Medical Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2019]]},"DOI":"10.1620\/tjem.248.87","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T18:04:26Z","timestamp":1560189866000},"page":"87-97","source":"Crossref","is-referenced-by-count":9,"title":["Expression Profiling of Receptor-Activator of Nuclear Factor-Kappa B Ligand in Soft Tissue Tumors"],"prefix":"10.1620","volume":"248","author":[{"given":"Tetsuro","family":"Yamagishi","sequence":"first","affiliation":[{"name":"Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ogose","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Uonuma Kikan Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ariizumi","sequence":"additional","affiliation":[{"name":"Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Oike","sequence":"additional","affiliation":[{"name":"Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Niigata Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Niigata Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riuko","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Histopathology Core Facility, Niigata University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Umezu","sequence":"additional","affiliation":[{"name":"Division of Pathology, Niigata University Medical and Dental Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Ajioka","sequence":"additional","affiliation":[{"name":"Histopathology Core Facility, Niigata University Faculty of Medicine"},{"name":"Division of Molecular and Diagnostic Pathology, Niigata University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Endo","sequence":"additional","affiliation":[{"name":"Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"622","reference":[{"key":"1","unstructured":"Boyce, A.M., Chong, W.H., Yao, J., Gafni, R.I., Kelly, M.H., Chamberlain, C.E., Bassim, C., Cherman, N., Ellsworth, M., Kasa-Vubu, J.Z., Farley, F.A., Molinolo, A.A., Bhattacharyya, N. &amp; Collins, M.T. (2012)  Denosumab treatment for fibrous dysplasia.  <i>J. Bone Miner. Res<\/i>., 27, 1462-1470."},{"key":"2","unstructured":"Branstetter, D., Rohrbach, K., Huang, L.Y., Soriano, R., Tometsko, M., Blake, M., Jacob, A.P. &amp; Dougall, W.C. (2015)  RANK and RANK ligand expression in primary human osteosarcoma.  <i>J. Bone Oncol<\/i>., 4, 59-68."},{"key":"3","unstructured":"Cohen, R.B., Hahn, G.V., Tabas, J.A., Peeper, J., Levitz, C.L., Sando, A., Sando, N., Zasloff, M. &amp; Kaplan, F.S. (1993)  The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients.  <i>J. Bone Joint Surg. Am<\/i>., 75, 215-219."},{"key":"4","unstructured":"Davenport, C., Harper, E., Forde, H., Rochfort, K.D., Murphy, R.P., Smith, D. &amp; Cummins, P.M. (2016)  RANKL promotes osteoblastic activity in vascular smooth muscle cells by upregulating endothelial BMP-2 release.  <i>Int. J. Biochem. Cell Biol<\/i>., 77, 171-180."},{"key":"5","doi-asserted-by":"crossref","unstructured":"Feinblatt, J.S., Berend, K.R. &amp; Lombardi, A.V. Jr. (2005)  Severe symptomatic heterotopic ossification and dislocation: a complication after two-incision minimally invasive total hip arthroplasty.  <i>J. Arthroplasty<\/i>, 20, 802-806.","DOI":"10.1016\/j.arth.2004.12.048"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., Jiang, Q., Tadros, S., Dansey, R. &amp; Goessl, C. (2011)  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.  <i>Lancet<\/i>, 377, 813-822.","DOI":"10.1016\/S0140-6736(10)62344-6"},{"key":"7","unstructured":"Fletcher, C.D.M., Bridge, J.A., Hogendoorn,P.C.W. &amp; Mertens, F.(2013)  <i>WHO classification of tumours of soft tissue and bone<\/i>, 4th ed., World Health Organization, Lyon, pp. 348-349."},{"key":"8","unstructured":"Gutierrez, A. Jr. &amp; Wetter, D.A. (2012)  Calcinosis cutis in autoimmune connective tissue diseases. <i>Dermatol. Ther<\/i>., 25, 195-206."},{"key":"9","doi-asserted-by":"crossref","unstructured":"Henry, D.H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., Scagliotti, G.V., Sleeboom, H., Spencer, A., Vadhan-Raj, S., von Moos, R., Willenbacher, W., Woll, P.J., Wang, J., Jiang, Q.,  et al. (2011)  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.  <i>J. Clin. Oncol<\/i>., 29, 1125-1132.","DOI":"10.1200\/JCO.2010.31.3304"},{"key":"10","unstructured":"Huang, L., Xu, J., Wood, D.J. &amp; Zheng, M.H. (2000)  Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.  <i>Am. J. Pathol<\/i>., 156, 761-767."},{"key":"11","doi-asserted-by":"crossref","unstructured":"Kartsogiannis, V., Zhou, H., Horwood, N.J., Thomas, R.J., Hards, D.K., Quinn, J.M., Niforas, P., Ng, K.W., Martin, T.J. &amp; Gillespie, M.T. (1999)  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.  <i>Bone<\/i>, 25, 525-534.","DOI":"10.1016\/S8756-3282(99)00214-8"},{"key":"12","unstructured":"Kawano, Y., Ueno, S., Abe, M., Kikukawa, Y., Yuki, H., Iyama, K., Okuno, Y., Mitsuya, H. &amp; Hata, H. (2012)  TRAIL produced from multiple myeloma cells is associated with osteolytic markers.  <i>Oncol. Rep<\/i>., 27, 39-44."},{"key":"13","unstructured":"Lewiecki, E.M. (2010)  Clinical use of denosumab for the treatment for postmenopausal osteoporosis.  <i>Curr. Med. Res. Opin<\/i>., 26, 2807-2812."},{"key":"14","unstructured":"Lin, M.E., Chen, T.M., Wallingford, M.C., Nguyen, N.B., Yamada, S., Sawangmake, C., Zhang, J., Speer, M.Y. &amp; Giachelli, C.M. (2016)  Runx2 deletion in smooth muscle cells inhibits vascular osteochondrogenesis and calcification but not atherosclerotic lesion formation.  <i>Cardiovasc. Res<\/i>., 112, 606-616."},{"key":"15","doi-asserted-by":"crossref","unstructured":"Pelle, D.W., Ringler, J.W., Peacock, J.D., Kampfschulte, K., Scholten, D.J. 2nd, Davis, M.M., Mitchell, D.S. &amp; Steensma, M.R. (2014)  Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.  <i>Transl. Res<\/i>., 164, 139-148.","DOI":"10.1016\/j.trsl.2014.03.005"},{"key":"16","unstructured":"Rinotas, V., Niti, A., Dacquin, R., Bonnet, N., Stolina, M., Han, C.Y., Kostenuik, P., Jurdic, P., Ferrari, S. &amp; Douni, E. (2014)  Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice.  <i>J. Bone Miner. Res<\/i>., 29, 1158-1169."},{"key":"17","doi-asserted-by":"crossref","unstructured":"Scotto di Carlo, F., Divisato, G., Iacoangeli, M., Esposito, T. &amp; Gianfrancesco, F. (2018)  The identification of H3F3A mutation in giant cell tumour of the clivus and the histological diagnostic algorithm of other clival lesions permit the differential diagnosis in this location.  <i>BMC Cancer<\/i>, 18, 358.","DOI":"10.1186\/s12885-018-4291-z"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Tajima, S., Koda, K. &amp; Fukayama, M.(2015)  Primary leiomyosarcoma of the breast with prominent osteoclastic giant cells: a case expressing receptor activator of NF-kappaB ligand (RANKL).  <i>Pathol. Int.<\/i>, doi 10.1111\/pin.12328.","DOI":"10.1111\/pin.12328"},{"key":"19","unstructured":"Taylor, C.R., Branstetter, D., Manna, E., Dougall, W.C., Bussiere, J. &amp; Johnson, C.W. (2017)  Distribution of RANK and RANK ligand in normal human tissues as determined by an optimized immunohistochemical method.  <i>Appl. Immunohistochem. Mol. Morphol<\/i>., 25, 299-307."},{"key":"20","unstructured":"Terasaki, M., Terasaki, Y., Yoneyama, K., Kuwahara, N., Wakamatsu, K., Nagahama, K., Kunugi, S., Takeshita, T. &amp; Shimizu, A. (2015)  Uterine leiomyosarcoma with osteoclast-like giant cells associated with high expression of receptor activator of nuclear factor kappaB ligand.  <i>Hum. Pathol<\/i>., 46, 1679-1684."},{"key":"21","unstructured":"Thomas, D.M. &amp; Skubitz, K.M. (2009)  Giant cell tumour of bone.  <i>Curr. Opin. Oncol<\/i>., 21, 338-344."},{"key":"22","unstructured":"Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T. &amp; Higashio, K. (1997)  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.  <i>Biochem. Biophys. Res. Commun<\/i>., 234, 137-142."},{"key":"23","doi-asserted-by":"crossref","unstructured":"Yamagishi, T., Kawashima, H., Ogose, A., Ariizumi, T., Sasaki, T., Hatano, H., Hotta, T. &amp; Endo, N. (2016)  Receptor-activator of nuclear KappaB ligand expression as a new therapeutic target in primary bone tumors.  <i>PLoS One<\/i>, 11, e0154680.","DOI":"10.1371\/journal.pone.0154680"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N.,  et al. (1998)  Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL.  <i>Proc. Natl. Acad. Sci. USA<\/i>, 95, 3597-3602.","DOI":"10.1073\/pnas.95.7.3597"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/248\/2\/248_87\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T23:40:53Z","timestamp":1560555653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/248\/2\/248_87\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.248.87","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}